Abstract:Although systemic mTOR inhibition improves age‐related physiological dysfunction, the cell types that mediate the beneficial effects remain elusive. Here, we demonstrate that endothelial cell‐specific reduction of mTOR ameliorates arterial and metabolic function in old age. These improvements are concomitant with reduced senescence burden, inflammation, and oxidative stress in arteries, lung, adipose tissue, and liver. These results support the exploration of therapeutic strategies targeting endothelial mTOR signaling. Systemic inhibition of the mammalian target of rapamycin (mTOR) delays aging and many age‐related conditions including arterial and metabolic dysfunction. However, the mechanisms and tissues involved in these beneficial effects remain largely unknown. Here, we demonstrate that activation of S6K, a downstream target of mTOR, is increased in arteries with advancing age, and that this occurs preferentially in the endothelium compared with the vascular smooth muscle. Induced endothelial cell‐specific deletion of mTOR reduced protein expression by 60–70%. Although this did not significantly alter arterial and metabolic function in young mice, endothelial mTOR reduction reversed arterial stiffening and improved endothelium‐dependent dilation (EDD) in old mice, indicating an improvement in age‐related arterial dysfunction. Improvement in arterial function in old mice was concomitant with reductions in arterial cellular senescence, inflammation, and oxidative stress. The reduction in endothelial mTOR also improved glucose tolerance in old mice, and this was associated with attenuated hepatic gluconeogenesis and improved lipid tolerance, but was independent of alterations in peripheral insulin sensitivity, pancreatic beta cell function, or fasted plasma lipids in old mice. Lastly, we found that endothelial mTOR reduction suppressed gene expression of senescence and inflammatory markers in endothelial‐rich (i.e., lung) and metabolically active organs (i.e., liver and adipose tissue), which may have contributed to the improvement in metabolic function in old mice. This is the first evidence demonstrating that reducing endothelial mTOR in old age improves arterial and metabolic function. These findings have implications for future drug development.

The mTOR signaling pathway in cardiac aging

Mammalian target of rapamycin is essential for cardiomyocyte survival and heart development in mice.

The Multifaceted Role of Nutrient Sensing and mTORC1 Signaling in Physiology and Aging

mTOR and Aging: An Old Fashioned Dress

Hyperactive mTORC1/4EBP1 signaling dysregulates proteostasis and accelerates cardiac aging

Mtor Signaling in Cardiometabolic Disease, Cancer, and Aging

Hyperactive mTORC1/4EBP1 Signaling Dysregulates Proteostasis and Accelerates Cardiac Aging.

With TOR, Less is More: A Key Role for the Conserved Nutrient-Sensing TOR Pathway in Aging

mTORC2: A neglected player in aging regulation

Mechanistic target of rapamycin in regulating macrophage function in inflammatory cardiovascular diseases

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy

Mtor and S6k Play an Important Role in Ageing

Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy

Identification of Reduced mTOR T1262 Phosphorylation as a Novel Mechanism and Therapeutic Target of Apoptosis in Senescent Cardiomyocytes: Aging and Cardiomyocyte Apoptosis

Persistent mTORC1 signaling in cell senescence results from defects in amino acid and growth factor sensing

Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

The mammalian target of rapamycin pathway and its role in molecular nutrition regulation.

Targeting the biology of aging with mTOR inhibitors

Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy

Endothelial cell‐specific reduction in mTOR ameliorates age‐related arterial and metabolic dysfunction

Hypothalamic Mtorc2 is Essential for Metabolic Health and Longevity